These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 8443401)
1. Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Garcia-Giralt E; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A; Guerin D; Guerin R Breast Cancer Res Treat; 1992; 24(2):139-45. PubMed ID: 8443401 [TBL] [Abstract][Full Text] [Related]
2. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]. Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956 [TBL] [Abstract][Full Text] [Related]
3. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. Canney PA; Priestman TJ; Griffiths T; Latief TN; Mould JJ; Spooner D J Natl Cancer Inst; 1988 Sep; 80(14):1147-51. PubMed ID: 2970555 [TBL] [Abstract][Full Text] [Related]
4. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Petru E; Schmähl D Klin Wochenschr; 1987 Oct; 65(20):959-66. PubMed ID: 2963170 [TBL] [Abstract][Full Text] [Related]
5. Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG+MPA in generalized breast cancer. Samonis G; Margioris AN; Bafaloukos D; Razis DV Oncology; 1994; 51(5):411-5. PubMed ID: 8052481 [TBL] [Abstract][Full Text] [Related]
6. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer. van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943 [TBL] [Abstract][Full Text] [Related]
7. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477 [TBL] [Abstract][Full Text] [Related]
8. [Current status of hormonotherapy of metastatic cancer of the breast]. Namer M Bull Cancer; 1989; 76(1):65-73. PubMed ID: 2713517 [TBL] [Abstract][Full Text] [Related]
9. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Smith IE; Harris AL; Morgan M; Ford HT; Gazet JC; Harmer CL; White H; Parsons CA; Villardo A; Walsh G; McKinna JA Br Med J (Clin Res Ed); 1981 Nov; 283(6304):1432-4. PubMed ID: 6797571 [TBL] [Abstract][Full Text] [Related]
10. A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone. Alberto P; Mermillod B; Kaplan E; Goldhirsch A; Obrecht JP; Jungi F; Martz G; Barrelet L; Cavalli F Eur J Cancer Clin Oncol; 1985 Apr; 21(4):423-8. PubMed ID: 3891359 [TBL] [Abstract][Full Text] [Related]
11. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405 [TBL] [Abstract][Full Text] [Related]
12. Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. Mercer PM; Ebbs SR; Fraser SC; Coltart RS; Bates T Eur J Surg Oncol; 1993 Jun; 19(3):254-8. PubMed ID: 8314383 [TBL] [Abstract][Full Text] [Related]
13. [Progestational agents and bone metastasis in breast cancer]. Leriche N; Bonneterre J Bull Cancer; 1997 Sep; 84(9):891-4. PubMed ID: 9435812 [TBL] [Abstract][Full Text] [Related]
14. Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation. Pronzato P; Rubagotti A; Amoroso D; Bertelli G; Queirolo P; Sertoli MR; Rosso M; Gallotti P; Monzeglio C; Rosso R Am J Clin Oncol; 1993 Dec; 16(6):522-5. PubMed ID: 8256770 [TBL] [Abstract][Full Text] [Related]
15. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Alonso-Muñoz MC; Ojeda-González MB; Beltran-Fabregat M; Dorca-Ribugent J; López-López L; Borrás-Balada J; Cardenal-Alemany F; Gómez-Batiste X; Fabregat-Mayol J; Viladiu-Quemada P Oncology; 1988; 45(5):350-3. PubMed ID: 3045726 [TBL] [Abstract][Full Text] [Related]
16. Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide. Brufman G; Isacson R; Haim N; Gez E; Sulkes A Oncology; 1994; 51(3):258-61. PubMed ID: 8196908 [TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment. Bezwoda WR; Derman DP; Browde S; Goss G; Lange M S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525 [TBL] [Abstract][Full Text] [Related]
19. Tamoxifen and aminoglutethimide in the management of patients with advanced endometrial carcinoma not responsive to medroxyprogesterone. Quinn MA; Campbell JJ; Murray R; Pepperell RJ Aust N Z J Obstet Gynaecol; 1981 Nov; 21(4):226-9. PubMed ID: 6951563 [TBL] [Abstract][Full Text] [Related]
20. Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment. Murray RM; Pitt P Breast Cancer Res Treat; 1981; 1(2):91-5. PubMed ID: 7348572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]